[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367732-105":59,"doc-detail-367732-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","integrated-transcriptomic-and-functional-modeling-reveals-akt-and-mtor-synergy-in-colorectal-cancer","Integrated transcriptomic and functional modeling reveals AKT and mTOR synergy in colorectal cancer","","Colorectal cancer (CRC) therapy is constrained by genetic heterogeneity and resistance. A drug discovery pipeline was built using patient-derived primary CRC cultures reflecting molecular features of primary and metastatic disease more faithfully than standard immortalized lines. Engineered and patient-based models captured tumor complexity, enabling high-throughput screening of 4,255 compounds to identify 33 selective candidates. Everolimus and uprosertib showed AKT–mTOR synergy at clinically relevant concentrations with improved scalability, cost-efficiency, and predictive accuracy via machine learning.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/integrated-transcriptomic-and-functional-modeling-reveals-akt-and-mtor-synergy-in-colorectal-cancer/367732/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/integrated-transcriptomic-and-functional-modeling-reveals-akt-and-mtor-synergy-in-colorectal-cancer/367732.png","ImageObject",300,407,{"name":92,"@type":93},"supergirl","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are patient-derived CRC cultures used instead of standard immortalized cell lines?","Question",{"text":113,"@type":114},"They better preserve the complexity and heterogeneity of primary tumors, including features not observed in immortalized lines. This improves clinical relevance for therapeutic evaluation.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What did the high-throughput screening identify?",{"text":118,"@type":114},"Screening 4,255 compounds yielded 33 agents with selective efficacy against CRC cells while sparing normal healthy epithelial cells.",{"name":120,"@type":111,"acceptedAnswer":121},"How do everolimus and uprosertib contribute to the proposed treatment strategy?",{"text":122,"@type":114},"The study reports promising synergy between the mTOR inhibitor everolimus and the AKT inhibitor uprosertib at clinically relevant concentrations, producing favorable therapeutic windows across patient-derived cultures.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},367732,1790217768,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962088121634,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nIntegrated transcriptomic and functional modeling reveals AKT and mTOR synergy in colorectal cancer  \nMarcin Duleba1􀀍, Eliza Zimoląg1, Joanna Szuszkiewicz1, Marcin Serocki1, Joanna Szklarczyk1, Olga Dracz1, Alexander Kurzejamski1, Izabella Więckowska1, Marcelina Chmiel1, Barbara Lipert1, Katarzyna Sarad1, Joanna Krawczyk1,  \nOleksii Bryzghalov1, Agata Stachowicz-Wałaszek1, Karolina Pyziak1, Joanna Drozdowska1, Krzysztof Baczyński1, Konrad Wojtowicz2, Maurycy Chronowski2, Krzysztof Rataj2, Magdalena Otrocka2, Michał Mikula3, Paula Feliksiak4, Rafał Dziadziuszko4,  \nTomasz Rzymski1, Andrew Thomason1, Krzysztof Brzózka1 & Andrzej Mazan1􀀍  \nColorectal cancer (CRC) treatment remains challenging due to genetic heterogeneity and resistance mechanisms. To address this, we developed a drug discovery pipeline using patient-derived primary CRC cultures with diverse genomic profiles. These cultures closely resemble certain molecular characteristics of primary and metastatic CRC, highlighting their promise as a translational platform for therapeutic evaluation. Importantly, our engineered model and patient-derived cells reflect the complexity and heterogeneity of primary tumors, not observed with standard immortalized cell lines, offering a more clinically relevant system, although further validation is needed. High-throughput screening (HTS) of 4255 compounds identified 33 with selective efficacy against CRC cells, sparing normal, healthy epithelial cells. Among the tested combinations, everolimus (mTOR inhibitor) and uprosertib (AKT inhibitor) demonstrated promising synergy at clinically relevant concentrations, with favorable therapeutic windows confirmed across tested patient-derived cultures. Notably, this synergy, revealed through advanced models, might have been overlooked in traditional immortalized cell lines, highlighting the translational advantage of patient-derived systems. Furthermore, the integration of machine learning into the HTS pipeline significantly improved scalability, cost-efficiency, and predictive accuracy. Our findings underscore the potential of patient-derived materials combined with machine learning-enhanced drug discovery to advance personalized therapies. Specifically, mTOR-AKT inhibition emerges as a promising strategy for CRC treatment, paving the way for more effective and targeted therapeutic approaches.  \nColorectal cancer (CRC) is a major public health concern, ranking as the third most prevalent cancer worldwide. In 2020, CRC was responsible for 10% of all cancer diagnoses, amounting to approximately 1,931,590 new cases 1. Interestingly, the incidence ofCRC shows a demographic split: it has been decreasing among older adults but is on the rise among younger individuals1,2. This shift emphasizes the importance of understanding CRC across different age groups, especially since early-stage detection can dramatically improve patient outcomes. In the United States, the five-year survival rate for CRC patients stands at about 63% and drops to 13% when diagnosed at an advanced stage3. This statistic highlights the critical role of timely diagnosis, as early detection significantly improves patient outcomes. At the core of CRC’s development is a series of genetic mutations affecting the epithelial tissues of the colon and rectum. These mutations involve key genes such as APC, KRAS, TP53, and SMAD4 and propel the disease along one of three molecular pathways: chromosomal instability, microsatellite instability, or the CpG island methylator phenotype4,5. Each pathway affects crucial cellular processes like DNA mismatch repair, cell cycle regulation, and apoptosis, underlining the complexity ofCRC’s molecular basis6,7.  \n1Ryvu Therapeutics, Kraków, Poland. 2Ardigen, Kraków, Poland. 3Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland. 4Medical University of Gdańsk, Gdansk, Poland. 􀀍 email:  \n[marcin.duleba@","cbCaidbBzMuPcLY3","https://ap.wps.com/l/cbCaidbBzMuPcLY3","pdf",7463029,17,"English","# Background and clinical need\n# Patient-derived primary culture platform\n## Model rationale versus immortalized cell lines\n## High-throughput screening results\n# AKT and mTOR inhibition strategy\n# Machine learning–enhanced drug discovery\n# Genomic drivers and mutation burden","[{\"question\":\"Why are patient-derived CRC cultures used instead of standard immortalized cell lines?\",\"answer\":\"They better preserve the complexity and heterogeneity of primary tumors, including features not observed in immortalized lines. This improves clinical relevance for therapeutic evaluation.\"},{\"question\":\"What did the high-throughput screening identify?\",\"answer\":\"Screening 4,255 compounds yielded 33 agents with selective efficacy against CRC cells while sparing normal healthy epithelial cells.\"},{\"question\":\"How do everolimus and uprosertib contribute to the proposed treatment strategy?\",\"answer\":\"The study reports promising synergy between the mTOR inhibitor everolimus and the AKT inhibitor uprosertib at clinically relevant concentrations, producing favorable therapeutic windows across patient-derived cultures.\"}]","Integrated transcriptomic and functional modeling reveals AKT and mTOR synergy in colorectal cancer | PDF",1790172305,43,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f05afac7a3c3e658fe0b950d7bc0ba8.webp",983,1291,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4755e85c43039c0d04d9c01a2027758b.webp",982,1290,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5371f095ff9a1e92b97bd9ac244230c2.webp",981,1289,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d9ba8d3d162d48cd647b7f88e91c950.webp",980,1287]